CuraGen Corporation (NASDAQ: CRGN), a biopharmaceutical company, is devoted to improving the lives of patients by developing pharmaceutical products that address medical needs that are currently unmet. The company’s therapeutics are based on the research of novel drug targets and mechanisms that are believed to play a role in underlying diseases. Through its efforts, CuraGen has utilized this research and understanding to develop a pipeline of protein, antibody, and antibody-drug conjugate drugs. For further information, visit the Company’s web site at www.curagen.com.
- 17 years ago
QualityStocks
CuraGen Corporation (NASDAQ: CRGN)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…